Immutep Acquires SymbioCelltics to Boost Cancer Drug Development
Ticker: PRRUF · Form: 6-K · Filed: Jul 15, 2024 · CIK: 1506184
| Field | Detail |
|---|---|
| Company | Immutep Ltd (PRRUF) |
| Form Type | 6-K |
| Filed Date | Jul 15, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, biotech, drug-development, manufacturing
TL;DR
Immutep buys SymbioCelltics for cash + potential raise to speed up its cancer drug, eftilagimod alpha.
AI Summary
Immutep Ltd. announced on July 12, 2024, that it has entered into a binding agreement to acquire all outstanding shares of SymbioCelltics Pty Ltd. This acquisition is expected to be completed by September 30, 2024, and will be funded through a combination of Immutep's existing cash reserves and a potential future capital raise. The deal aims to accelerate Immutep's development of its lead product candidate, eftilagimod alpha, by integrating SymbioCelltics' cell line development and manufacturing capabilities.
Why It Matters
This acquisition could accelerate the development and potential commercialization of Immutep's cancer therapies by bringing crucial manufacturing and cell line expertise in-house.
Risk Assessment
Risk Level: medium — The acquisition's success depends on successful integration and the company's ability to secure future funding if needed.
Key Numbers
- N/A — Acquisition Price (Specific dollar amount not disclosed in this filing, but funded by cash and potential raise.)
Key Players & Entities
- Immutep Ltd. (company) — Acquiring company
- SymbioCelltics Pty Ltd (company) — Acquired company
- eftilagimod alpha (drug_candidate) — Immutep's lead product candidate
- September 30, 2024 (date) — Expected closing date of acquisition
- July 12, 2024 (date) — Announcement date
FAQ
What is the primary strategic rationale behind Immutep's acquisition of SymbioCelltics?
The acquisition is intended to accelerate Immutep's development of its lead product candidate, eftilagimod alpha, by integrating SymbioCelltics' cell line development and manufacturing capabilities.
When is the expected completion date for the SymbioCelltics acquisition?
The acquisition is expected to be completed by September 30, 2024.
How will the acquisition of SymbioCelltics be funded?
The acquisition will be funded through Immutep's existing cash reserves and a potential future capital raise.
What specific capabilities does SymbioCelltics bring to Immutep?
SymbioCelltics brings cell line development and manufacturing capabilities.
Has Immutep previously been known by another name?
Yes, Immutep Limited was formerly known as Prima BioMed Ltd, with a name change date of November 19, 2010.
Filing Stats: 264 words · 1 min read · ~1 pages · Grade level 17.3 · Accepted 2024-07-12 19:01:56
Filing Documents
- d729734d6k.htm (6-K) — 9KB
- d729734dex991.htm (EX-99.1) — 20KB
- g729734dsp4.jpg (GRAPHIC) — 9KB
- g729734dsp4a.jpg (GRAPHIC) — 5KB
- 0001193125-24-178664.txt ( ) — 51KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: July 12, 2024 IMMUTEP LIMITED By: /s/ Marc Voigt Name: Marc Voigt Title: Chief Executive Officer